Publication, Publications Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation
Publication, Publications Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles
Publication, Publications Establishment of a robust rat hepatitis E virus fecal-oral infection model and validation for antiviral studies
ALG-000184, Publications CAM-E ALG-000184, Treatment for up to 24 weeks with the capsid assembly modulator ALG-000184 results in dose related reductions in HBsAg in subjects with HBeAg positive chronic hepatitis B
Other, Publications siRNA ALG-125755, Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in subjects with chronic hepatitis B
Other, Publications siRNA ALG-125755, Pharmacodynamic durability of ALG-125755, a GalNAc-conjugated siRNA, correlated with total and RNA induced complex (RISC) bound siRNA in mouse liver
Preclinical, Publications Small molecule PD-L1 inhibitor ALG-093702, Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models
Preclinical, Publications siRNA PD-L1 inhibitor, A potent human PD-L1 siRNA leads to significant reduction of AAV-HBV infected hepatocytes via immune activation in human PD-1/PD-L1 double knock in mice
Preclinical, Publications Hepatitis B virus model system, An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients
Preclinical, Publications Hepatocellular carcinoma, Selective inhibition of human β-catenin DNA transactivation activity using splice switching oligonucleotides for an improved therapeutic window in treating hepatocellular carcinoma